Comparative effectiveness of incident oral antidiabetic drugs on kidney function

Kidney International

Volumn 81, Issue 7, 2012, Pages 698-706

  Hung, Adriana M ^a,b   Roumie, Christianne L ^a,b   Greevy, Robert A ^a,b   Liu, Xulei ^a,b   Grijalva, Carlos G ^b   Murff, Harvey J ^a,b   Ikizler, T Alp ^a,b   Griffin, Marie R ^a,b  

^a Geriatric Research Education Clinical Center (GRECC)   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

chronic kidney disease; diabetes; diabetic nephropathy

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS;

EID: 84862777052     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.444     Document Type: Article

References (50)

1. Levey AS, Atkins R, Coresh J et al. Chronic kidney disease as a global public health problem: Approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72: 247-259.
2. Collins AJ, Foley RN, Herzog C et al. Excerpts from the US renal data system 2009 annual data report. Am J Kidney Dis 2010; 55: S1-420 A426-427.
3. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
4. Hallan SI, Dahl K, Oien CM et al. Screening strategies for chronic kidney disease in the general population: Follow-up of cross sectional health survey. BMJ 2006; 333: 1047.
5. Brocco E, Velussi M, Cernigoi AM et al. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. J Nephrol 2001; 14: 461-471.
6. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
7. Levin SR, Coburn JW, Abraira C et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. veterans affairs cooperative study on glycemic control and complications in type 2 diabetes feasibility trial investigators. Diabetes Care 2000; 23: 1478-1485.
8. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
9. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
10. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
11. Bakris G, Viberti G, Weston WM et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12.
12. Bakris GL, Ruilope LM, McMorn SO et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006; 24: 2047-2055.
13. Bennett WL, Maruthur NM, Singh S et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613.
14. Hung AM, Roumie CL, Greevy RA et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function in veterans with type 2 diabetes mellitus. Am Soc Nephrol. Meeting 2010 Poster.
15. Bolen S, Feldman L, Vassy J et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
16. Chen J, Muntner P, Hamm LL et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14: 469-477.
17. Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347.
18. Kobayashi S, Maesato K, Moriya H et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005; 45: 275-280.
19. Nerpin E, Riserus U, Ingelsson E et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care 2008; 31: 1550-1555.
20. Shoji T, Nishizawa Y. Chronic kidney disease as a metabolic syndrome with malnutrition-need for strict control of risk factors. Intern Med 2005; 44: 179-187.
21. Trirogoff ML, Shintani A, Himmelfarb J et al. Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3-4 chronic kidney disease patients. Am J Clin Nutr 2007; 86: 1642-1648.
22. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
23. Descamps-Latscha B, Herbelin A, Nguyen AT et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995; 154: 882-892.
24. Fried L, Solomon C, Shlipak M et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 2004; 15: 3184-3191.
25. Shlipak MG, Katz R, Cushman M et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med 2005; 118: 1416.
26. Tonelli M, Sacks F, Pfeffer M et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-245.
27. Caravaca F, Cerezo I, Macias R et al. Insulin resistance in chronic kidney disease: Its clinical characteristics and prognosis significance. Nefrologia 2010; 30: 661-668.
28. Morales AI, Detaille D, Prieto M et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int 2010; 77: 861-869.
29. Ishani A, Xue JL, Himmelfarb J et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
30. Okusa MD, Chertow GM, Portilla D. The nexus of acute kidney injury, chronic kidney disease, and World Kidney Day 2009. Clin J Am Soc Nephrol 2009; 4: 520-522.
31. Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-28.
32. Juhaeri J, Stevens J, Chambless LE et al. Associations between weight gain and incident hypertension in a bi-ethnic cohort: The atherosclerosis risk in communities study. Int J Obes Relat Metab Disord 2002; 26: 58-64.
33. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001; 59: 1498-1509.
34. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the american diabetes association and the european association for the study of diabetes. Diabetologia 2009; 52: 17-30.
35. Navaneethan SD, Yehnert H, Moustarah F et al. Weight loss interventions in chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 1565-1574.
36. Navarro-Diaz M, Serra A, Romero R et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: Long-term follow-up. J Am Soc Nephrol 2006; 17: S213-S217.
37. Huizinga MM, Roumie CL, Greevy RA et al. Glycemic and weight changes after persistent use of incident oral diabetes therapy: A veterans administration retrospective cohort study. Pharmacoepidemiol Drug Saf 2010; 19: 1108-1112.
38. Holman RR, Paul SK, Bethel MA et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
39. Kahn SE, Lachin JM, Zinman B et al. Effects of rosiglitazone, glyburide, and metformin on {beta}-cell function and insulin sensitivity in ADOPT. Diabetes 2011; 60: 1552-1560.
40. Imano E, Kanda T, Nakatani Y et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-2139.
41. Nakamura T, Ushiyama C, Osada S et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50: 1193-1196.
42. Lachin JM, Viberti G, Zinman B et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 2011; 6: 1032-1040.
43. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol 2003; 158: 915-920.
44. Roumie CL, Huizinga MM, Liu X et al. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: A retrospective cohort. Pharmacoepidemiol Drug Saf 2010; 20: 36-44.
45. Jones CA, McQuillan GM, Kusek JW et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-999.
46. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
47. Bash LD, Coresh J, Kottgen A et al. Defining incident chronic kidney disease in the research setting: The ARIC Study. Am J Epidemiol 2009; 170: 414-424.
48. Beck GJ, Berg RL, Coggins CH et al. Design and statistical issues of the modification of diet in renal disease trial. the modification of diet in renal disease study group. Control Clin Trials 1991; 12: 566-586.
49. Fried LF, Duckworth W, Zhang JH et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009; 4: 361-368.
50. Arnold N, Sohn M, Maynard C et al. VIReC technical report 2: VA NDI mortality data merge project. In: Hines IL, Edward Hines Jr VA (eds). Hospital VA Information Resource Center 2006. Available at http:// www.virec.research.va. gov/References/TechnicalReports/VIReCTechnicalReports.htm.